Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes
- Results showed a reduction in body weight of up to a mean of 4.2% from baseline vs body weight increase of 0.6% with PBO-treated participants while the plasma half-life of ZP8396 was 230hrs., suitable for QW administration with no serious AEs and no withdrawals
- The first-in-human single ascending dose study was designed to assess the safety, PK, and PD effects of ZP8396 in healthy lean and overweight people with a mean BMI of 25.8 were randomized (6:2) within 7 cohorts and treated with either ZP8396 (SC) or PBO
- ZP8396 is an amylin analogue designed to improve solubility, minimize fibrillation and co-formulate with other peptides. A P-Ib multiple ascending dose study is ongoing and the company expects to report topline results in the H2’23
Ref: zealand-pharma| Image: zealand-pharma
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].